8/14/2019 080114 protaffin technology profile

1/1

CellJammerdiscovery technology

Our Aim:

To develop novel anti-

inflammatory biologicals

by targeting endothelial

surface glycan structures

for the first time.

Relevant Targets

Relevant targets share

property of binding toglycans (GAGs). Initial

focus is on chemokines

but with wider applications.

Process

Design and development

of protein-based GAG

antagonists, taking 6

months from start to in

vivocharacterisation.

Advantages

Faster development of

specific therapeutics than

with glycan-based drugs,

easier manufacturing and

specificity more easily

achieved

Business Model

ProtAffin works with

partners to co-develop

therapeutics with usual

milestone payments and

royalty entitlements

Collaborations

We are currentlycollaborating with leading

universities and are

seeking Pharma/Biotech

collaborations

Overview

ProtAffin Biotechnologie AG has

developed the novel CellJammer

discovery technology for developing

anti-inflammatory and other products.

We will work with Pharma/Biotech

companies to apply our technology to

their targets of interest.

Technology

ProtAffins co-Founder, Prof. Andreas

Kungl is a leader in the field ofprotein-glycan interactions. Over the

last 10 years, it has been shown that

protein-glycan (i.e. Protein-GAG)

interactions drive many acute and

chronic inflammatory processes.

ProtAffin has developed the

CellJammer discovery technology to

create proteins with improved binding

to disease-related GAGs, thereby

acting as potent, targeted anti-

inflammatory products (ref.1).

Model of an IL-8 monomer bound to a

GAG oligosaccharide

Chemokines rely on protein-GAG

interactions for efficiently driving

cellular inflammation in diseases such

as ischemia/reperfusion injury and

rheumatoid arthritis. ProtAffin is

initially applying its discovery

technology to chemokines for the

development of anti-inflammatory

products (ref. 2).

Process

ProtAffin uses the CellJammer

discovery technology to create protein-

based GAG antagonists. We use

structural bioinformatics for rational

design of mutants, followed by

proprietary assays to select optimal

therapeutics. We achieve an increase

in GAG-binding affinity, without

changing the specificity of GAG

binding. Secondly, we inactivate the

target protein, e.g. by knocking-out theGPCR activity of chemokines.

Following in vitroand cell-based

characterisation, we work with

partners to characterise the

pharmacology of the proteins in ex

vivoand in vivodisease models.

Advantages

A number of companies have

developed monoclonal antibodies to

GAG-binding proteins. This

complication in target biology providesthe chance to create superior

therapeutics to mAbs when dealing

with this significant class of complex

proteins. ProtAffin offers a new, fast

track way to target protein-glycan

interactions, avoiding the need for

complex carbohydrate chemistry and

expensive manufacturing scale-up.

References1) Gesselbauer & Kungl, Curr. Op. Mol.

Therap. 8, 521 (2006)

2) Potzinger et al., Biochem. Soc.

Transact. 34, 435 (2006)

Contact: ProtAffin Biotechnologie AG

Impulszentrum Graz-West, Reininghausstrasse 13a

A-8020 Graz, Austria

Web: www.protaffin.com

Tel: +43 316 382 541

E-mail: office@protaffin.com

Target Characterisation:

Various indicationsUndisclosed

Partners

Target Characterisation:

Various indicationsUndisclosed

Partners

DiscoveryIn vitro

studies

In vivo

modelsPre-clinical

development Phase IDiseaseindication

IL-8CellJammer

PA04-001

I/R injury in transplantRA, others

Chemokine 2

CellJammer

PA05-008

Various

Chemokine 3CellJammerPA05-017

Various

Various

Target 4CellJammer

PA06-001

January 2008

http://www.protaffin.com/http://www.protaffin.com/